Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
April 28, 2022 at 03:55 am EDT
Share
Jiangsu Sihuan Bioengineering Co., Ltd reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 50.36 million compared to CNY 70.88 million a year ago. Revenue was CNY 50.36 million compared to CNY 70.88 million a year ago. Net loss was CNY 23.28 million compared to CNY 13.27 million a year ago. Basic loss per share from continuing operations was CNY 0.0226 compared to CNY 0.0129 a year ago. Diluted loss per share from continuing operations was CNY 0.0226 compared to CNY 0.0129 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.